ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIBGet Free Report) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 9,200 shares, a growth of 5.7% from the August 31st total of 8,700 shares. Based on an average daily volume of 13,500 shares, the days-to-cover ratio is currently 0.7 days.

ProShares Ultra Nasdaq Biotechnology Trading Down 1.0 %

Shares of BIB opened at $63.10 on Wednesday. ProShares Ultra Nasdaq Biotechnology has a one year low of $40.10 and a one year high of $69.56. The stock has a 50 day moving average price of $65.02 and a 200 day moving average price of $59.76.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The company also recently declared a dividend, which will be paid on Wednesday, October 2nd. Investors of record on Wednesday, September 25th will be given a dividend of $0.1528 per share. This is a boost from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.04. The ex-dividend date is Wednesday, September 25th.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

Large investors have recently made changes to their positions in the company. Clarity Capital Partners LLC purchased a new stake in ProShares Ultra Nasdaq Biotechnology in the 4th quarter valued at $201,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in ProShares Ultra Nasdaq Biotechnology in the 1st quarter valued at $288,000. Westwood Wealth Management purchased a new stake in ProShares Ultra Nasdaq Biotechnology in the 1st quarter valued at $575,000. Finally, Toth Financial Advisory Corp grew its holdings in ProShares Ultra Nasdaq Biotechnology by 132.3% in the 1st quarter. Toth Financial Advisory Corp now owns 26,111 shares of the exchange traded fund’s stock valued at $1,502,000 after buying an additional 14,870 shares in the last quarter.

ProShares Ultra Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Read More

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.